Replication-deficient retroviruses have been successfully utilized as vectors, offering an efficient, stable method of therapeutic gene delivery. Many examples exist proving this mode of integrative gene transfer is both effective and safe in cultured systems and clinical trials. Along with their success, severe side effects have occurred with early retroviral vectors causing a shift in the approach to vector design before further clinical testing. Several alternative delivery methods are available but lentiviral vectors (LV) are among the most favorable as they are already well understood. LV offer safer integration site selection profiles and a lower degree of genotoxicity, compared with g-retroviral vectors. Following their introduction, development of the self-inactivating vector configuration was a huge step to this mode of therapy but did not confer full protection against insertional mutagenesis. As a result integration, modeling must be improved to eventually avoid this possibility. The cellular factor LEDGF/p75 seems to play an essential role in the process of LV site selection and its interactions with chromatin are being quickly resolved. LEDGF/p75 is at the center of one example directed integration effort where recombinant products bias the integration event, a step toward fully directed integration into pre-determined benign loci. A more accurate picture of the details of LEDGF/p75 in the natural integration process is emerging, including new binding specificities, chromatin interaction kinetics and additional cellular factors. Together with next-generation sequencing technology and bio-informatics to analyze integration patterns, these advancements will lead to highly focused directed integration, accelerating wide-spread acceptance of LV for gene therapy.
INTRODUCTION
Engineering retroviruses into vectors of therapeutic value has been a highly pursued effort. To date, the promise of retroviralmediated gene delivery to treat or even cure genetic diseases has been demonstrated in animal models and the clinic. Despite present accomplishments and vector design improvements such as the self-inactivating mechanism, testing in humans has not gone without serious consequences. Most notoriously, the emergence of cancer in several patients enrolled in a gretroviral-mediated clinical trial for X-linked SCID (severe combined immunodeficiency) has forced current vector systems to be reconsidered. There is mounting support by many groups that turning to lentiviral vectors (LVs), especially HIV-1, over those based on other retroviral taxa may provide enough success to promote gene therapy to an acceptable and safe treatment.
The first two sections of this review will briefly focus on the most recent and successful applications of LVs in both pre-clinical experiments and clinical trials, discussing their broad therapeutic uses, advantages and disadvantages over other available vectors.
An ideal retroviral vector system is one where integration can be directed to avoid potential oncogenesis. In order to achieve this, much work has gone into elucidating integration site selection (ISS) and the mechanism behind host chromatin targeting. The current model involves molecular tethering of the virus to chromatin by the host factor LEDGF/p75 but it remains partial. Recent insights to its role in ISS provide a more complete picture of this process.
Finally, improvements toward directed vector integration will be discussed. Despite setbacks, this modern molecular therapy has proven worthy with its broad applications and in improving quality of life.
LVS DISPLAY AN EFFECTIVE MODE OF GENE TRANSFER IN PRE-CLINICAL EXPERIMENTS
Vector engineers have successfully exploited the integrative property of lentiviruses to incorporate nucleic acid into the chromosomes of non-replicating or terminally differentiated cells. Lentiviral pre-integration complexes can pass through intact nuclear envelopes via active transport mechanisms for access to host DNA, making them useful for gene therapy approaches in a broad range of tissues. [1] [2] [3] [4] Gene delivery by vectors based on other viruses such as the adeno-associated virus (AAV) also show promise but clear advantages and drawbacks exist to their production, administration and safety profiles. For example, LV production faces titer limitations compared with AAVs, while LV are more immunologically benign. Additionally, the LV therapeutic payload can be B10 kb while AAV can tolerate only B5 kb, further opening it to larger gene products and more extensive regulatory elements. 5 Pre-clinical work on LV prove them as an effective method of stable foreign gene delivery.
Retinal and cardiac tissue provide two examples where absent gene function is restored with LV. Both HIV-1 and SIV vectors are able to stably transduce dysfunctional retinal pigment epithelium in rats, with no signs of local or systemic toxicity. 6, 7 Histological analysis revealed signs of retinal repopulation and transgene expression similar to normal human retina. 8 Cardiac diseases have also been approached using LV. Fabry disease, a recessive mutation in the a-galactosidase A gene leads to the lethal accumulation of globotriaosylceramide (Gb3) in cardiac tissue. 9 Intravenous injection of a LV carrying a functional a-gal A gene under the control of cardiac-specific promoters not only resulted in elevated expression of the transgene in mouse cardiac tissue, but also showed decreased levels of Gb3 after several weeks. 9, 10 Among the many defective cell types that have been approached by LV technology, it is important to acknowledge successful pre-clinical work in abnormal hematopoietic stem cells (HSC) that manifest as immunodeficiencies, primary targets for such therapy. Demonstrating efficient phenotype correction in these cells holds weight over other cell targets.
Wiskott-Aldrich syndrome arises from the loss of function of the protein with the same name (WASp), which results in several autoimmunities and predispositions to cancers. 11 Experimental transduction with a LV in was null mouse HSCs demonstrated stable transgene expression into five blood cell lineages 12 months post-infusion with no cancers resulting directly from tranduction. 11 Adding to its pre-clinical safety profile, transduced human WAS, CD34
þ cells showed normal engraftment and differentiation into immunodeficient mice. 12 Partial and/or full correction of cystic fibrosis, neurological disorders involving glia, oligodendrocytes and astrocytes and immunodeficiency involving dysfunctional HSCs have all been demonstrated in animal models with several of them approaching or are presently involved in phase I clinical trials. [13] [14] [15] [16] In addition, in vivo LV animal studies have shown even the possibility of in utero or neo-natal gene therapy, further broadening their applications and window for administration. 17, 18 LVS HAVE BEEN CLINICALLY TESTED DEMONSTRATING SAFE AND SUCCESSFUL OUTCOMES It should not go without stating that LV are not the only systems that have made it to clinical testing. AAVs have been adapted with reasonably positive outcomes toward treating dysfunctional retina as seen with the improvement in the eyesight and with acceptable adverse event profiles in three patients with advanced Leber's congenital amaurosis (LCA2). 19 The phase 2 CUPID trial where calcium regulation was corrected in a number of patients with heart failure provides another example of AAV-mediated gene therapy. 20 Despite the success of the trials, previously documented AAV immunogenicity in certain circumstances warranted a shift to LV technology in part to its low immunestimulating properties. 9 Interrupting wild-type (wt) HIV-1 transmission and slowing the progression of AIDS has been a huge challenge using conventional pharmacologic approaches. HIV-1-based vectors offer a unique approach to curtail wt-HIV replication within the infected host. A 2003 phase 1 clinical trial provided direct evidence for this by using a recombinant HIV-based vector carrying an anti-sense payload complimentary to the wt-HIV env gene. 21 Patients enrolled in the trial were found to have no adverse events (that is, replication competent lentivirus formation, insertional mutagenesis, vector mobilization) 18 months post-infusion again supporting how non-toxic these therapies can be. 22, 23 In addition, the five subjects experienced differential changes to their viral loads, one displaying an approximate 2 log reduction. 21 The lack of apparent vector-mediated physiologic disruption deserves deeper investigation into this treatment for slowing AIDS progression.
A new innovative method using LVs to stimulate T-lymphocytes against tumor-specific antigen provides another clinical example. In 2010, three patients with advanced chronic lymphoid leukemia received infusions of their own genetically modified lymphocytes infected with an HIV-based vector to express a novel CAR (chimeric antigen receptor). T-cells expressing the CAR, upon contact with CD19 would become activated and expand producing a population specific for B-cell destruction. Despite low-grade systemic reactions, two of three patients experienced full remission of their condition. 24 T-cells were found to express the CAR at least 6 months post-infusion and evidence of memory cells were found in the bone marrow, which may indicate long-term survival. 24 Moreover, no serious adverse events were experienced; insertional mutagenesis was not detected for 10 months, up to the time of publication. 24 ISS CONFERS DIFFERENTIAL GENOTOXICITY BETWEEN RETROVIRUSES GIVING A MAJOR ADVANTAGE TO LV-BASED GENE THERAPY MLV-based vectors have shown some degree of success in a clinical trial for curing adenosine deaminase-deficient SCID. The trial had no fatal outcomes and 9 out of the 10 subjects showed immune reconstitution. 25 Unfortunately, the results for the X-linked SCID trial in 2000, involving the same vector system did not produce such a promising outcome. Disruption of normal physiological expression of proto-oncogenes in the treated HSCs was observed giving rise to a novel vector-mediated T-cell malignancy in four of these patients, one being a fatal case. [26] [27] [28] While vector design contributes to oncogenesis, the insertional mutagenic events are largely attributed to the integration site preferences of the virus itself. 29 Thus, differences in site selection have been linked to varying genotoxic potentials of vector systems. [29] [30] [31] ISS could be defined as the process of the viral pre-integration complex (PIC) 'seeking out' the position within the host genome to covalently insert its genome (in the case of RV vector therapy, the gene of interest). Many aspects of the virus/vector system and the target cells affect ISS and studying such trends is no easy task. Molecular techniques exist to detect proviral loci but these sites do not necessarily reflect actual integrative preferences. Several or even many initial IS may be missed due to abortive integration events and this must be considered.
There is strong evidence from several independent parties that g-retroviruses prefer sites in close proximity to promoters while HIV-1 and other lenti-proviruses are found throughout transcription units with no preference for promoters. 32, 33 It is believed that the powerful transcriptional enhancing properties of the natural gretroviral LTRs, combined with its IS preferences stimulated expression of nearby proto-oncogenes and is partially responsible for its elevated genotoxicity and oncogenic potential. 29, 34 These conclusions lead to self-inactivating vector (SIN) systems, where the enhancing property of the LTRs are destroyed, leaving the transgene expression driven by an internal promoter. When compared with LVs with active LTRs, the SIN vectors showed a remarkable decrease in aberrant splicing in HSCs, which can cause clonal dominance. 35 Even with the SIN improvement, g-retroviral vectors can still transform mouse HMCs as per an in vitro genotoxicity assay, and do not show significant oncogenic reduction in animal models. 30, 36 Thus, an appropriate engineered vector should not only have regulatory elements to better contain transcriptional spillover, but should also carry a mechanism that alters the inherent ISS as both of these aspects contribute to insertional mutagenesis.
LV and g-retroviral vectors do not show equivalent rates of tumorigenesis even with the same genetic payload in animal models. When analyzed in Cdkn2a À / À tumor-prone mouse cells, g-retroviral vectors induced dose-dependent tumor acceleration, which was not observed with LV. 37 Shortly after, this model was used to compare the oncogenic potential of a g-retroviral vector and an HIV-based vector on the same footing by controlling for differences in enhancement strength of activated LTRs using hybrid vectors. The LV still showed a lower oncogenic potential, highlighting the importance of vector ISS on malignant transformation. 29 They concluded overall that LVs are safer by a factor of 10. 29 This further adds to the safety profile of HIV-1-based vectors.
Although these recent experiments elegantly show lower toxicity of LVs, oncogenesis still must be expected, as there are no documented absolute restrictions for LV integration into the vicinity of oncogenes. Two patients receiving the adrenoleukodystrophy protein gene via an HIV-1 vector did not present with clinically apparent leukemia but common integration sites were detected in lymphocytes following their treatment. 16 This raises flags in that clonal instability may eventually arise, leading to more serious complications. Although it is likely that integration bias gave rise to these common integration sites, selection advantage cannot be absolutely ruled out. 38 The 2012 review by Biasco et al. 39 further discusses common integration sites and their role in transformation in a clinical context.
Despite their reliability, recent publications have shown that LV treatment may not be as benign as once thought. LV transduced cells have been shown to cause aberrant transcripts when the vector integrates into specific splice sites and can even cause malignant transformation in mice by insertional haploinsufficiency. 40, 41 Whether these phenomena has or will occur in human trials is unclear. The next logical step in the development of safer vectors is to scrutinize their integration sites to determine what governs the site selection and to better predict clinical outcomes.
UNDERSTANDING TRENDS OF HIV-1 ISS
The integration reaction can be performed in vitro and is useful on a small scale, with respect to few aspects of target sites such as the effects of nucleosome complex formation or primary sequence characteristics. [42] [43] [44] [45] [46] [47] Due to complex higher-order packaging of chromatin and its association with many host proteins, analysis of IS in cultured cells provides a more accurate method for describing site selection and sites of particular interest. For instance, in building an insertional dominance database from HSCs, significant overlaps were found between retroviral integration sites and highly expressed genes flagged in the retrovirustagged cancer gene database. 48 The publication of the human genome in 2001 allowed for the first time genome-wide integration mapping. In 2002, the first evidence of non-random integration of wtHIV-1 and a derived vector, with a highly significant preference for inserting into genes. 32 Soon thereafter came similar investigations of other retroviruses and vectors. In 2003, the ISS of HIV were compared with that of MLV showing its preference for transcriptional start sites and CpG islands, elements associated with gene promoters while ASLV (avian sarcoma leukosis virus) showed yet another, more random ISS pattern. 33, [49] [50] [51] Simian and feline immunodeficiency viruses, both belonging to the lentivirus taxa, show similar site preferences to HIV supporting unique and genera specific ISS mechanisms. 52, 53 Primary sequence seems not to be a dominating feature in governing ISS as only weak palindromic nucleotide preferences and avoidances were found for HIV-1, MLV and ASLV with no absolute restrictions. 54 Interestingly, nucleotide preference patterns immediately surrounding HIV-1 integration sites were the same in in vitro and in vivo experiments, suggesting that it may play a minor role in the natural ISS mechanism. 55 Moving past primary sequence, specific genetic and epigenetic features have been identified associated with and avoided by lentiviruses. The histone code has become well defined in its ability to alter chromatin configuration and many of these marks have been linked with the transcriptional activity of the associated sequence. 56 In 2007, with the extensive genomic annotation by the ENCODE project, over 40 000 HIV-1 integration sites were mapped and correlated with transcriptional activating histone modifications including acetylation of H3 and H4 and methylation on lysine 4 of H3 (Figure 1) . 57 Furthermore, trimethylation of H3K27, a transcriptionally inhibiting modification, was statistically avoided. 57 Interestingly, HIV-1 and MLV-based vectors do avoid the H3K27me3 mark but at different rates in similar cell types in a window of o10 kbs. 58, 59 These tight associations between HIV integration sites reveal specific biological targets above primary sequence that the virus could utilize to enter transcriptionally active DNA. This trend is 60 where this group in part, reproduced the positive and negative correlations between the integration sites of lentivirus, equine infectious anemia virus (EIAV) and histone modifications described by Wang in 2007, adding over 40 others (Figure 1 ). Whether PICs interact with epigenetic features directly or indirectly, through chromatin remodeling proteins, for example, is unclear and it is possible that although significant, these epigenetic patterns are found to be a byproduct of vector site selection.
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As discussed previously, MLV's preference for promoter regions and HIV's preference for integration anywhere along transcription units may indicate separate targeting mechanisms. On the other hand, strikingly similar associations were found between HIV and MLV proviral sites and the modifications H3K4me1, H3K4me3 and H3K9ac. 61 The fact that these different viruses share histone code preferences but differ in a number of other aspects leads to the logical conclusion that some overlap may exist in the integration mechanisms but specific host factors influence integration in each case. Recently, a statistically rigorous methodology has been described to compare integration 'hotspots' between HIV and MLV that may provide further conclusions when comparing them to histone modifications and gene clusters. 62 Interestingly, this group found a previously unidentified HIV-1 hotspot in hematopoietic progenitor cells on chromosome 6, corresponding to the major histocompatability complex locus, that was not seen in MLV site selection. They also determined that HIV-1 hotspots are generally broader and more gene dense than those from MLV, confirming previous reports from other cells and analytical methods. 62 These methods could eventually be applied to describe subtle correlations between retroviral IS and histone modifications at very specific loci to improve integration preference modeling.
IMPROVING HIV ISS MODELING
Several models have been proposed that may contribute to the site preferences of lentiviruses, the earliest of which involved physical accessibility of chromatin to the PIC. Direct visualization of fluorescently labeled PICs to decondensed chromatin at the nuclear periphery over more central chromatin shows how nuclear substructure likely plays a role in integration. 63 But this model is not enough to explain the substantial differences in ISS between viruses. Another consideration for affecting ISS is of course, cell-cycle effects. Populations of dividing cells display nonsynchronous fluctuations in chromatin structure due to DNA synthesis and chromosome segregation. Comparing IS of an HIV-1-based vector in non-dividing macrophages to other collections retrieved from mitotic T-lymphocytes showed a slight decrease in the preference for transcription units but essentially no differences in ISS with respect to repeat elements (that is, LINEs, Alu and MIR SINEs) 64 Furthermore, a slight increase in the preference for intragene, CpG rich and GC-dense regions was observed for HIV in activated over resting CD4 þ T cells and in dividing over growtharrested IMR-90 lung fibroblasts. 59, 65 Work by Bartholomae et al.
66
also shows LV IS preference for gene coding regions in mouse fibroblasts and HSC while near random integration with respect to genes were found within post-mitotic brain and ocular tissues, indicating again a minor role for cellular activity in ISS. Although these contributions may affect proviral loci modestly, only a lentiviral specific, molecular tethering model can account for the gross differences in viral ISS and still follow histone code associations. LEDGF/p75 has been identified as a major player in lentiviral ISS and has been extensively studied for its interactions with HIV IN. [67] [68] [69] This factor is a transcriptional coactivator involved in the regulation of stress response genes. 70 LEDGF/ p75 co-immunoprecipitates with lentiviral PICs and has been shown to bind only IN from this retroviral genera including HIV-1, 2 and FIV, excluding integrase molecules from HTLV-2, MoMLV and Rous sarcoma virus. 67, 68 Experimental HIV infections in LEDGF/ p75 siRNA knockdown and LEDGF/p75 null cells have intriguing effects on the ISS of HIV making it a primary candidate to verify a tethering factor model. For instance, infections of LEDGF/p75 knockdown cells force viral integrase relocation to the cytoplasm, losing its chromatin association. 67 Furthermore, in studies where directed mutagenesis of viral genes disrupts IN/LEDGF/p75 interaction, integration was highly disrupted. 69, 71 Stronger support comes from LEDGF/p75 knockout cell lines. Here in the absence of residual expression, integration still takes place but at a highly reduced rate and the viral preference for transcription units is lost. (Figure 1 ) 72, 73 Additional genetic features of HIV-1 IS are also altered under these conditions (see Figure 1 and associated references).
The structure of LEDGF/p75 has been thoroughly described (for review see Engelman and Cherepanov 74 ) . The current tethering model involves an intimate association of the integrase-binding domain to the PIC through integrase, while N-terminal domains (PWWP, CR1) interact with features of chromatin guiding the complex to the resulting viral integration sites via this specificity. 75, 76 The entity acting as the receptor of the LEDGF/ p75-viral complex is largely unknown. It seems that the histone code can provide a wide range of binding targets that assume specific regulatory function to which LEDGF can recognize. Unfortunately, the ENCODE project has only been applied to 1% of the genome and the lack of specific natural DNA-binding sites for LEDGF/p75 severely limits efforts to make genome-wide, direct connections to histone modifications. Despite these limitations, LEDGF/p75 chromatin-binding profiles were still constructed in this 1%, at a resolution of 1-3 kb using DamID technology. 77 Interestingly, this group showed that 75% of LEDGF/p75-binding islands were within transcription units, while avoiding TSS (transcriptional start site). 77 Although consistent with HIV-1 integration profiles, they conclude that this finding contradicts the current understanding of the co-factors function, as it was believed to stimulate the expression of stress response genes by TSS binding. 78 Nevertheless, this finding may help explain HIV's preference for integration anywhere along transcription units. More detailed descriptions of LEDGF-binding sites and their associated epigenetic marks are needed for stronger conclusions. New insights to LEDGF/p75 function and natural binding targets may aid it its understanding in HIV chromatin targeting.
A novel supercoiled-DNA recognition domain of LEDGF/p75 was recently characterized both in vitro and in vivo displaying preferential binding to negatively supercoiled-DNA, inherent to the transcription process. 79 With the established associations between LEDGF/p75 and H3K4me (present on histones throughout transcription units) and this newly described affinity for DNA structure in the transcriptional complex, the implications of LEDGF/p75's role in HIV ISS are huge. These findings give a new consideration to explaining how HIV integrates into openly transcribed DNA, anywhere within the range of transcription without regard to intron/exon discrimination.
Both recent in vitro and in vivo assays were developed to examine the dynamic interactions of LEDGF/p75, HIV IN and DNA/ chromatin. A new application of AlphaScreen technology has been used to quantitatively determine that LEDGF/p75 significantly increases the binding affinity of HIV-1 IN to mock viral cDNA 10 to 30-fold. 80 Furthermore, in the same report, introduction of LEDGF containing mutated AT-hooks/NLS actually decreased the affinity of IN for DNA past the point where no LEDGF was present. 80 These findings show the importance of the individual factors in contributing to the integration mechanism as a whole. In conjunction with this study, a new real-time in vivo assay has revealed some interesting details of the dynamic kinetics of LEDGF/p75/HIV IN and chromatin. Using fluorescently labeled LEDGF, the factor displayed typical intranuclear chromatin scanning. When complexed with HIV IN, the affinity of LEDGF to chromatin increases B75-fold slowing its migration through chromatin. 81 This group also suggests that considering distribution kinetics, two units of LEDGF/p75 may be present in each PIC, which may further influence ISS.
Finally, although LEDGF has a central role in ISS of HIV, other unexpected host factors come into the picture as altering their expression induces drastic changes in site preferences. One example of this indicates that nuclear import of the PIC and the factors controlling this event can influence integration loci. Transportin-3 and RanBP2 are both factors involved in nuclear import and assist in translocation of HIV PICs through the nuclear envelope. 82, 83 Using shRNA depletion of both these factors in independent experiments before infections, recovered integration sites were found in loci with greatly decreased gene density. 84 These results suggest that a more complete integration-targeting model may involve a great number of host factors contributing to the dominant activity of LEDGF/p75 and may even begin before viral nuclear import.
It has been shown that the chromatin-targeting model is more complex than originally described. Whether the PIC directly binds/ interacts with epigenetic modifications on decondensed chromatin or if the interaction exists indirectly through another factor is unclear. There are many factors involved in this process, that is, HMGA1, Ini-1, Hsp60, BAF and chromatin remodeling proteins, especially in the absence of LEDGF/p75. The PIC (including LEDGF/ p75) does seem to follow specific epigenetic modification patterns associated with decondensed chromatin. Considering the weak but certainly recognizable primary sequence preferences epigenetic interactions may be involved in the last stages of targeting, in the chromatin microenvironment, before viral strand transfer. Current modeling should primarily work to clarify these epigenetic interactions.
DIRECTED INTEGRATION EFFORTS
An integrated provirus can disrupt normal cellular gene expression by two mechanisms. The first is due to mutations in the DNA sequence itself with the addition of the transgene leading to loss of function, while the other involves regulatory changes in the transcription of neighboring genes from the vector's promoter activity. These major obstacles must be avoided for acceptable therapeutic LV use. Ideally, a vector construct would contain a mechanism/factor that allows efficient integration into a welldefined locus were the side effects mentioned can be absolutely avoided. Heavy manipulation and engineering of viral and host factors have been tested in order to direct the integration event and several methods show proof of concept that ISS can be altered.
Some of the earliest attempts at directed integration involved integrase fusion proteins containing bacterial chromatin-binding domains (CBDs) specific for primary sequence. [85] [86] [87] Fusion products showed a shift in integration to the product's target sites in vitro but efforts were complicated when directed integration was attempted in cultured cells. Packaging of such proteins became a limiting factor as particles failed to incorporate IN-fusion products during vector production making transduction of the product into target cells impossible. 88 This problem was solved by fusing the product to viral Vpr and incorporated into particles in trans. Recently, incorporation of HIV IN-fusion proteins into fully infectious particles was demonstrated without the need for Vpr fusion. Reporter genes were added in-frame behind the IN gene on the vector's packaging construct, where during the vector production itself, fusion proteins were incorporated into the particles, which were fully infectious. 89 This has yet to be performed with a modified IN that can direct integration in cultured cells but it is an advancement in heterologous protein packaging.
Working off the current LEDGF chromatin-targeting mechanism, several laboratories have demonstrated directed integration in cells by using engineered tethering factors. Integration into a well-defined locus cannot yet be done, but shifting the preference of LVs into transcriptionally inactive DNA (that is, heterochromatin) is a favorable step toward this outcome. This should decrease unwanted regulatory disruption lowering the probability for insertional mutagenesis. Three publications show proof of concept that by expressing recombinant LEDGF/p75-based tethering factors, integration can be shifted to regions that display the target of the CBDs possessed by the fusion proteins. First, Silvers et al. 90 constructed a tethering factor by replacing the chromatin recognition domain (PWWP) of LEDGF/p75 with that from heterochromatin binding protein 1a (HP1a), which recognizes the H3K9me3 modification (Figure 2) . By expressing this protein in 293T cells before vector infection, they showed a significant decrease in the number of their intragene IS (76.9-59.7%). To further show that the virus had altered its ISS, an increase in the frequency of LINEs (long interspersed nuclear elements; strongly associated with untranscribed DNA) were found near their recovered IS; from 7.8 to 16.3%. 89 Similar results were seen with the expression of another HP1a/LEDGF tethering factor where RefSeq intragene integration dropped from 67.6 to 34.2%, approaching a rate comparable to random integration. 91 Together, these latest advancements show that directed integration can be performed and with further manipulation of LEDGF/p75 with other CBDs, fully directed integration may be achieved. A next logical step would be to move these tethering factors into in vivo studies and perhaps into a tumor-prone or even LEDGF/p75 null mouse model to study if these tethering factors can actually reduce oncogenic potential.
Hybrid vector systems, such as those composed of integrasedeficient LVs containing Sleeping Beauty transposases or designer ZFN (zinc-finger nucleases) are efficient at directing integration in addition tethering factors. The transposase (that is, SB100X) can effectively override the natural integration process and direct it at a rate mirroring randomized integration, a property that should decrease insertional mutation risks. [92] [93] [94] ZFN hybrid systems are promising as they can induce double-stranded breaks at specific loci but packaging limitations exist. 95 
CONCLUSIONS
Where current invasive procedures often result in partial correction and considerable probability for side effects, autologous gene therapy proves beneficial. As investigations in the early 2000's demonstrate, the therapy itself is not without side effects. Over the last decade, much attention has turned to LVs for therapeutic gene delivery due to its safety profile, transduction efficiency and relatively deep understanding of their biological mechanics.
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LEDGF/p75 LEDGF/p75/CBD Euchromatin Heterochromatin Figure 2 . The lentiviral pre-integration complex binds LEDGF/p75 before the integration of the viral DNA into genes and active transcription units. By expressing an engineered tethering factor based on LEDGF/p75 with a foreign N-terminal CBD specific for trimethylation on lysine 9 of histone H3 (H3K9me3), the integration event can be biased into silent heterochromatin (see text).
? H3K9me3
IN IN
LV-PIC
The explosive impact of biotechnology, specifically nextgeneration sequencing and bio-informatics/genomics on this field of research should be acknowledged. In the early 1990's, studies were being performed on the scale of dozens of retroviral IS at a time. 96 Due to technology such as massively parallel pyrosequencing, the number of IS that can be analyzed in a given time has increased 1000-fold catapulting analysis to a scale never before available. 57, 97 These genome-wide studies open the door to rigorous statistical analysis that may reveal once hidden ISS patterns. Efforts such as the ENCODE project should also be recognized as it provides the data that makes analytical associations to genetic and epigenetic elements possible. Not only is the availability of this body of information revolutionary, but also the way it can be displayed and utilized as it continues to grow (that is, UCSC Genome Browser).
As we continue into this new era of molecular therapy, organizations around the globe, including the NIH (National Institute of Health) and the European Medicines Agency are working to protect the integrity of the manufacturing and use of recombinant gene therapies. The transparent oversight system of the NIH extends requirements for all gene transfer proposals to go through the recombinant DNA advisory committee. The NIH Office of Biotechnology Activities holds public meetings to discuss issues in a setting where scientists and policy makers alike can exchange information to safely and more efficiently advance gene transfer research, while the EMEA has provided a regulatory framework for advanced therapy medicinal products throughout Europe since 2008. 98, 99 With the characterization of new LV systems and their ability to safely and reliably correct faulty phenotypes in the laboratory, there should be continued effort to move them into clinical testing. Issues such as avoiding the emergence of a novel retrovirus are of paramount importance but under the proper quality and monitoring standards, this technology can effectively extend quality of life. Over time, researchers and clinicians will work to improve risk/benefit ratios promoting LV-mediated gene therapy as well recognized and acceptable. There is great power and perhaps a touch of irony, as we work one of humanity's greatest killers into one of its most revolutionary medicines.
